
Search
Selected Filter
Filter Results
Displaying 81–90 of 508 news results
-
Sep 7, 2023
First Patient Dosed in LCA5 Gene Therapy Clinical Trial Launched by Opus Genetics
Opus was established by the RD Fund, the Foundation’s venture philanthropy arm
-
Sep 7, 2023
Foundation Funds 25 New Grants Totaling $15.1 Million in FY23
The global leader in retinal degenerative disease research supports a total of 93 research grants in its portfolio.
-
Sep 6, 2023
Therapeutic Targets for Dry AMD: A Foundation Fighting Blindness Webinar for Eye Care Professionals
The free, online event will feature a lecture from David Boyer, MD, a Senior Partner at Retina-Vitreous Associates Medical Group and dry AMD expert.
-
Aug 31, 2023
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
First cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Aug 28, 2023
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
The AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
Aug 22, 2023
FDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and Diabetic Retinopathy
New, higher treatment dose reduces frequency of eye injections for patients
-
Aug 5, 2023
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
In two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Aug 4, 2023
Karen Petrou Appointed Foundation Chair Effective July 1, 2024, Upon the Retirement of David Brint
Special Foundation Announcement from Jason Menzo
-
Jul 28, 2023
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
The company’s emerging, oral treatment is designed to slow vision loss
-
Jul 12, 2023
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
The emerging RNA therapy is designed to boost expression of the PRPF31 protein